L&K Biomed Statistics

Total Valuation

L&K Biomed has a market cap or net worth of KRW 116.83 billion. The enterprise value is 116.46 billion.

Market Cap	116.83B
Enterprise Value	116.46B

Important Dates

The next estimated earnings date is Thursday, August 14, 2025.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	n/a

Share Statistics

L&K Biomed has 19.94 million shares outstanding. The number of shares has increased by 21.17% in one year.

Current Share Class	19.94M
Shares Outstanding	19.94M
Shares Change (YoY)	+21.17%
Shares Change (QoQ)	-24.00%
Owned by Insiders (%)	13.27%
Owned by Institutions (%)	0.68%
Float	17.29M

Valuation Ratios

The trailing PE ratio is 23.02.

PE Ratio	23.02
Forward PE	n/a
PS Ratio	3.26
PB Ratio	3.13
P/TBV Ratio	2.72
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 32.36, with an EV/FCF ratio of -14.43.

EV / Earnings	20.88
EV / Sales	3.25
EV / EBITDA	32.36
EV / EBIT	118.93
EV / FCF	-14.43

Financial Position

The company has a current ratio of 1.64, with a Debt / Equity ratio of 0.65.

Current Ratio	1.64
Quick Ratio	0.86
Debt / Equity	0.65
Debt / EBITDA	6.20
Debt / FCF	-3.00
Interest Coverage	0.41

Financial Efficiency

Return on equity (ROE) is 19.41% and return on invested capital (ROIC) is 1.51%.

Return on Equity (ROE)	19.41%
Return on Assets (ROA)	1.11%
Return on Invested Capital (ROIC)	1.51%
Return on Capital Employed (ROCE)	2.81%
Revenue Per Employee	394.06M
Profits Per Employee	61.29M
Employee Count	60
Asset Turnover	0.50
Inventory Turnover	0.26

Taxes

Income Tax	-411.98M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -35.34% in the last 52 weeks. The beta is 1.86, so L&K Biomed's price volatility has been higher than the market average.

Beta (5Y)	1.86
52-Week Price Change	-35.34%
50-Day Moving Average	6,241.60
200-Day Moving Average	6,709.35
Relative Strength Index (RSI)	46.69
Average Volume (20 Days)	49,565

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, L&K Biomed had revenue of KRW 35.86 billion and earned 5.58 billion in profits. Earnings per share was 254.52.

Revenue	35.86B
Gross Profit	29.48B
Operating Income	1.28B
Pretax Income	6.22B
Net Income	5.58B
EBITDA	3.90B
EBIT	1.28B
Earnings Per Share (EPS)	254.52

Full Income Statement

Balance Sheet

The company has 17.95 billion in cash and 24.18 billion in debt, giving a net cash position of -6.24 billion or -312.89 per share.

Cash & Cash Equivalents	17.95B
Total Debt	24.18B
Net Cash	-6.24B
Net Cash Per Share	-312.89
Equity (Book Value)	37.30B
Book Value Per Share	2,202.38
Working Capital	25.35B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -6.92 billion and capital expenditures -1.15 billion, giving a free cash flow of -8.07 billion.

Operating Cash Flow	-6.92B
Capital Expenditures	-1.15B
Free Cash Flow	-8.07B
FCF Per Share	-404.86

Full Cash Flow Statement

Margins

Gross margin is 82.21%, with operating and profit margins of 3.57% and 15.55%.

Gross Margin	82.21%
Operating Margin	3.57%
Pretax Margin	17.34%
Profit Margin	15.55%
EBITDA Margin	10.87%
EBIT Margin	3.57%
FCF Margin	n/a

Dividends & Yields

L&K Biomed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-21.17%
Shareholder Yield	n/a
Earnings Yield	4.77%
FCF Yield	-6.91%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

L&K Biomed has an Altman Z-Score of 2.34 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.34
Piotroski F-Score	3